We’re on a mission to deliver remarkable experiences, making life better for patients taking part in clinical trials around the world.
The COVID-19 pandemic pushed patient centricity high on big pharma’s agenda, and it’s never been more important to listen to patient voices at every stage of the clinical journey.
Over the past year, we’ve evolved to meet the changing needs of the clinical research industry at an unprecedented rate. We’ve supported the uptake of decentralised clinical trials, grown and evolved our mobilehealth division, launched medical distribution centres in the EU and North America to carry out clinical trial visits in patients’ own homes.
Here’s a round up of what our remarkable team have achieved over the past 12 months, and what we are looking forward to in 2022 and beyond.
We’re investing hugely in R&D, developing healthcare technology that tackles the ongoing challenges our clients face at each stage of a clinical trial. From issues with patient care and sentiment, to home HCP visits and medical equipment, to burdensome payment workflows and reimbursements, our innovative technology directly improves patient experience and trial outcomes.
Primarius underpins all of our services, providing a central information hub and seamless, integrated experience for patients, caregivers, sponsors, and healthcare providers. We recently released Primarius 3, and next year the technology will evolve further to support healthcare practitioners with CPD, as well as streamlining all decentralised and site visits.
With technology at the centre of the mdgroup ecosystem, we can take the trial to the patient and the patient to the trial, delivering remarkable experiences at every touchpoint.
We launched Horreum, our medical distribution network based in the US and Europe, at the beginning of 2021. It’s been integral to the development of our mobilehealth services, allowing us to get high quality medical equipment, lab, nurse and patient kits to our team of nurses around the world during a time when supply distribution was often unreliable.
This has been a game changer for sponsors and their patients. It has allowed us to reliably support studies not just for COVID-19, but for many rare diseases where patients are relying on the continuation of their trials.
We are one of the founding organisations of the world’s first Decentralised Trials and Research Alliance (DTRA), developed in response to the cataclysmic shift the industry went through during the COVID-19 pandemic. We had to evolve faster than we ever have, which meant finding the sweet spot between patient care and technological advancement.
Our mobilehealth service puts nurses in patients’ homes, carrying out trial visits with the high standards of care we are known for, while using our in-house technologies to streamline processes and enhance the patient experience.
For decentralised clinical trials to be truly remarkable, we need the best talent to carry out the visits.
Seacole Health was evolved from an acquisition in 2021 as a talent agency for nurses and research professionals, providing training and rewarding opportunities with the support of the
global mdgroup team.
Our podcast and video series, mdtalk launched in the summer of 2021. It explores the most important issues impacting clinical trials, patients, and the medical research industry today.
This year, we’ve been exploring the importance of recruiting and retaining a diverse patient population, barriers to participation and our responsibility as an industry to ensure research is truly inclusive and accessible. We’re looking forward to welcoming more mdtalk guests in the new year, where we’ll continue to give a platform to patients and explore the patient experience – a topic very close to our heart.
We’re proud to have been recognised for our contribution to the clinical research sector, and to be shortlisted for the SCRIP Awards in the Best Specialist Contract Research Agency category.
This year, we’re 6th on the J.P.Morgan 200 Female-Powered Businesses list and the regional champion for our area and 11th on the 2021 Alantra Pharma Fast 50 list. We’re also featured on Buzzacott’s Organic Growth 25 list as one of the fastest organically growing companies in the United Kingdom.
We wouldn’t be where we are today without our exceptional team.
This year, we’ve extended our reach as far as Australia an other areas, and welcomed some of the industry’s finest into the mdfamily. Because of our team’s commitment to always go above and beyond to deliver remarkable patient experiences, we’ve successfully facilitated thousands of visits and impacted the lives of patients and their families taking part in clinical trials around the world. All this despite a global pandemic.